Coherus Oncology Inc (CHRS)

EBITDA Growth

27.44%

Quarterly · Period ending:

CHRS logo

CHRS EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported27.44%
CHRS Quarterly EBITDA YoY % (-138.82% → 27.44%)
High-resolution chart · PNG

CHRS ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc EBITDA Growth — Quarterly
Period endingEBITDA Growth
27.4411%
23.379%
2.516%
-973.5938%
-549.5156%
30.2929%
34.8001%
86.6916%
80.0287%
2.5466%
-40.3345%
63.0622%
24.9209%
24.6445%
-25.7823%
-145.1436%
-83.3777%
48.1238%
-322.9576%
-192.4561%
-135.0115%
-500.6692%
-63.1032%
-35.2137%
136.0244%
375.1739%
178.6059%
195.6781%
169.779%
63.1529%
-30.1817%
0.4369%
22.6409%
42.7613%
37.1472%
-164.1771%
16.8261%
-12.4868%
-42.0779%
222.8776%
-6.9959%
-56.7094%
-104.9698%
-817.1869%
-146.5582%
-81.9881%
-123.4931%
60.16%
-158.9113%
-138.8205%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.